Congratulations to Cycle Computing’s customers, and partners for receiving HPCwire Editors’ Choice Awards at SC14. Cycle Computing is honored to once again to be a part of these awards! The coveted awards are determined using a rigorous selection process from the editors of HPCwire. Cycle Computing, along with its customers and partners were nominated for seven different awards.
“The HPCwire Readers’ and Editors’ Choice Awards send a strong message of support and appreciation from those in the global HPC community. We are proud to be able to recognize these efforts each your and our congratulations go out to all the winners.”
– Tom Tabor, CEO of Tabor Communications, publisher of HPCwire
Our work with Novartis Institutes for Biomedical Research received two awards:
- EDITORS CHOICE BEST USE OF HPC IN THE CLOUD
- EDITORS CHOICE BEST USE OF HPC APPLICATION IN LIFE SCIENCES
You can read more about this use case here in this blog: Novartis Taps Cloud HPC for Faster Drug Discovery & Better Science.
Below is the description of the award-winning entry:
Cancer research identifying three promising compounds, done by Novartis Institute for Biomedical Research with Cycle Computing and Amazon Web Services
Novartis Institutes for Biomedical Research has benefitted from using HPC on-demand in the fight against cancer. As presented at the 2014 AWS Summit in New York, Novartis leveraged Cycle Computing software and AWS cloud infrastructure to accelerate its cancer research. The partners created a cloud-based super-cluster, valued at about $44 million, for less than $5,000. Novartis researchers used the virtual supercomputer to screen 10 million compounds, condensing 39 drug design years down to 11 hours. Most importantly: they identified three promising compounds, which made their way into the next stages of drug design.